Related Experiment Video

Updated: Apr 5, 2026

Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System
08:01

Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System

Published on: June 11, 2020

8.9K

Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases

Hui Fu1, Min Ni2, Ji-Kuai Chen1

  • 1Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai 200433, China.

Current Drug Targets
|August 26, 2015
PubMed

Insights

Targeting the alpha7 nicotinic acetylcholine receptor (α7nAChR) pathway may offer a new therapeutic approach for inflammatory conditions affecting the heart and brain. Activating this pathway shows promise in treating cardiovascular and cerebrovascular diseases.

Area of Science:

  • Cardiovascular Research
  • Neuroscience
  • Inflammation Biology

Background:

  • Cardio-cerebral-vascular diseases (CCVDs) are leading causes of global mortality.
  • Inflammation plays a critical role in the development of CCVDs like myocardial infarction, atherosclerosis, hypertension, and stroke.
  • The cholinergic anti-inflammatory pathway, regulated by the alpha7 nicotinic acetylcholine receptor (α7nAChR), is a key focus in CCVD research.

Purpose of the Study:

  • This review examines the role of α7nAChR in the pathology of myocardial infarction, atherosclerosis, hypertension, and stroke.
  • To consolidate current understanding of α7nAChR's involvement in major CCVDs.

Main Methods:

  • Literature review of existing studies on α7nAChR and CCVDs.
  • Analysis of research findings related to the activation and inhibition of α7nAChR in disease models.

Main Results:

  • Evidence suggests that activating α7nAChR is a potential therapeutic strategy for CCVDs.
  • Studies indicate α7nAChR activation can mitigate pathological processes in myocardial infarction, atherosclerosis, hypertension, and stroke.

Conclusions:

  • Modulating the α7nAChR pathway offers a novel therapeutic avenue for combating inflammation in CCVDs.
  • Targeting α7nAChR presents a promising strategy for future treatments of cardiovascular and cerebrovascular diseases.
Abstract

Keywords:
anti-inflammation targetcardio-cerebral-vascular diseaseshypertensioninflammationmyocardial infarctionα7nAChR

More Related Videos

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

1.9K
Probing Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices via Laser Flash Photolysis of Photoactivatable Nicotine10:48

Probing Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices via Laser Flash Photolysis of Photoactivatable Nicotine

Published on: January 25, 2019

9.8K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.6K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
6.0K
Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
6.6K